Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Text search

Sort by Random

Display 15 Products per page

Siliq
Read More
Although it met all its primary endpoints in the Phase III AMAGINE clinical trial program and

demonstrated superiority to the first-to-market interleukin (IL)-12/23 inhibitor Stelara (ustekinumab;

Johnson & Johnson), Siliq’s (brodalumab; AstraZeneca/Valeant Pharmaceuticals/Leo Pharma/Kyowa

Hakko Kirin) prospects in psoriasis are unfavorable primarily due to concerns associated with its safety

profile.
October 17, 2017
Find out more
Digital Health Technology and Regulatory Overview

$4,750.00

This technology report provides an overview of the current landscape for digital health devices and software. This includes a summary of regulation and reimbursement policies and highlights of major product categories.
December 13, 2021
Find out more
Lenvima
Read More
Lenvima (lenvatinib; Eisai/Novartis/Merck & Co) is an orally available small molecule inhibitor of multiple tyrosine kinases including vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR).
September 9, 2019
Find out more
Azeliragon
Read More
Azeliragon is an orally available small molecule that acts as an inhibitor of the receptor for advanced glycation endproducts (RAGE).
September 2, 2016
Find out more
Imbruvica
Read More
Imbruvica is an oral small molecule inhibitor of Bruton’s tyrosine kinase (BTK). BTK is part of the B-cell receptor signaling pathway, which promotes cell proliferation, adhesion, and survival in many B-cell malignancies.
January 31, 2019
Find out more
Farydak
Read More
Farydak (panobinostat; Novartis) is an orally available histone deacetylase (HDAC) inhibitor. Inhibition of HDAC leads to relaxed chromatin and increased transcription.
August 9, 2018
Find out more
Early Access to Medicines in the US and Europe

$2,995.00

Faced with pressure from stakeholders – particularly patients – governments, regulators, and some countries have introduced new options and/or processes to speed up access to medicines. This includes access before marketing authorization, and speeding up the marketing authorization, or less often, the health technology assessment processes.

July 15, 2019
Find out more
Disease Analysis: Wet Age-Related Macular Degeneration
Read More
Age-related macular degeneration (AMD) is the progressive degradation of the part of the eye responsible for visual acuity, causing a loss of central vision. AMD is the leading cause of blindness in individuals who are over 65 years old. As the chances of experiencing any form of AMD increase with age, treatment of this disease is becoming even more important as life expectancies continue to rise in most regions.
September 23, 2022
Find out more
Seebri Neohaler
Read More
Novartis, under license from Vectura and Sosei, developed Seebri Neohaler, a once-daily inhaled formulation of glycopyrrolate.
July 31, 2018
Find out more
Orbactiv
Read More
Orbactiv is a broad-spectrum antibiotic mainly targeting inpatient settings. The drug is a semisynthetic lipoglycopeptide that inhibits bacterial cell wall synthesis by blocking peptidoglycan biosynthesis.
September 10, 2014
Find out more
Diagnostic and Guided Interventional Cardiology Products Market

$4,750.00

This comprehensive medical market and technology report provides an overview and in-depth market analysis of diagnostic and guided interventional cardiology devices (specifically, transcatheter angiography, guidewire-based intravascular stenosis assessment, intracardiac echocardiography (ICE), intravascular ultrasound (IVUS), optical coherence tomography (OCT), and robotic-assisted surgical systems) used in the diagnosis of cardiovascular diseases (CVDs) and guidance of minimally invasive therapies.
July 31, 2017
Find out more
ALKS 5461
Read More
ALKS 5461 (Alkermes) is a fixed-dose combination of buprenorphine, a mu opioid receptor partial agonist and kappa opioid receptor antagonist, and samidorphan (ALKS 33), which is a proprietary opioid modulator.
March 29, 2019
Find out more
umbralisib
Read More
Umbralisib (TG Therapeutics/Rhizen) is a novel phosphoinositide 3-kinase (PI3K) delta inhibitor that also selectively inhibits casein kinase-1 (CK1) epsilon. Expression of the PI3K delta isoform plays a role in B-cell development and function, and is often overactivated in B-cell malignancies.
January 30, 2019
Find out more
Cimzia
Read More
Cimzia (certolizumab; UCB/Astellas [also marketed by Dermira in some approved indications]) is a PEGylated humanized monoclonal antibody fragment, with high affinity for both soluble and membrane-bound tumor necrosis factor alpha.
July 31, 2018
Find out more
UK Generics and Biosimilars

$2,995.00

Prescribing by international non-proprietary name, pharmacist incentives, and the high price differential between the brands and their generic alternatives are the key drivers of the generics market in the UK.
November 2, 2016
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *